MAAT INDEX

CLAIM #12203 · Bristol-Myers Squibb Company (BMY) · 2025Q3 earnings call · Oct 30, 2025 · due Jun 30, 2026

We have a Phase IV switch study that reads out early next year, all will help build physician confidence.

Adam Lenkowsky · Chief Commercialization Officer

CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
We have a Phase IV switch study that reads out early next year
Reported
We also reported positive Phase I switch data for cobi

Verify independently

SEC filings for BMY · Claim quote is verbatim from the 2025Q3 earnings call.